{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "pubchem:8223",
      "entity_text" : "ergotamine",
      "entity_type" : "simple_chemical"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ01820",
      "entity_text" : "CYP3A4 inhibitors",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Most cases are caused by interaction with CYP3A4 inhibitors, which increase ergotamine bioavailability at least fourfold.",
  "reading_complete" : "2020-08-04T13:24:13Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-04T13:06:39Z",
  "trigger" : "increase",
  "evidence" : [ "CYP3A4 inhibitors, which increase ergotamine" ],
  "pmc_id" : "3951637",
  "score" : 0
}